Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $184.6652W HIGH $281.07
Volume
6.18 M
Value Traded
2.34 B
Short % Float
0.88%
+0.18%Week
-3.97%1 Month
-0.19%3 Month
+7.56%6 Month
+36.78%5 Year
+37,394.82%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
618.09 B
EPS (TTM)
8.73
P/E Ratio
29.38
Ent. Value
646.37 B
Total Shares
2.41 B
Float Shares
2.41 B
Insiders
0.12%
Institutions
77.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
JNJ Catalyst Timeline
Dated clinical, regulatory and corporate events for Johnson & Johnson
Catalyst Timeline
Dated clinical, regulatory & corporate events for Johnson & Johnson
2030Total events
23Upcoming
1024Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP empfiehlt Zulassung einer Indikationserweiterung für TECVAYLI (teclistamab) bei RRMM nach mindestens einer vorherigen Therapie
rezidiviertes oder refraktäres multiples Myelom (RRMM)source ↗
▲Topline ReadoutCAPLYTAApprovedClinical Data
Positive topline results from pivotal Phase 3 Study 451 of CAPLYTA in bipolar I mania
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Primary Endpoint MetCAPLYTAApprovedClinical Data
Study 451 met primary endpoint with statistically significant 4.8-point greater YMRS reduction vs placebo at Week 3
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Secondary Endpoint DataCAPLYTAApprovedClinical Data
Significant improvement in CGI-S illness severity vs placebo at Week 3 (LSMD -0.5; P<.0001)
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
●Safety Data UpdateCAPLYTAApprovedClinical Data
CAPLYTA well-tolerated in Study 451 with safety profile consistent with established profile
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP recommends approval of TECVAYLI indication extension for RRMM after ≥1 prior therapy
relapsed/refractory multiple myeloma after at least one prior therapysource ↗
●Late-BreakerCAPLYTAApprovedPresentation
Study 451 findings presented in late-breaking presentation at 2026 Psych Congress Annual Meeting
manic episodes with or without mixed features in adults with bipolar I disordersource ↗
▲Topline ReadoutAmivantamabApprovedClinical Data
Final overall survival analysis of PAPILLON: median OS 34.3 months with amivantamab plus chemotherapy
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Topline ReadoutRYBREVANT®ApprovedClinical Data
Final overall survival analysis of PAPILLON presented at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Oral PresentationRYBREVANT®ApprovedPresentation
PAPILLON final OS results presented at IASLC 2026 WCLC Presidential Symposium (Late-breaking Abstract #PL.03.03)
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Late-BreakerAmivantamabApprovedPresentation
PAPILLON final OS results presented as late-breaking abstract at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancersource ↗
▲Oral PresentationAmivantamabApprovedPresentation
PAPILLON final OS results presented at IASLC 2026 WCLC Presidential Symposium
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
●Poster PresentationRYBREVANT®ApprovedPresentation
COPERNICUS prophylactic strategies data presented at WCLC 2026 (Abstract #MO12.09)
EGFR-mutated non-small cell lung cancersource ↗
●Poster PresentationPresentation
PALOMA-2 subcutaneous administration data presented at WCLC 2026 (Abstract #PT2.03.06)
EGFR-mutated non-small cell lung cancersource ↗
▲Topline ReadoutAmivantamabApprovedClinical Data
Final overall survival analysis of PAPILLON presented at WCLC 2026
EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
Johnson & Johnson receives CE marking for reusable ACUVUE OASYS MAX 2-Week contact lenses
▲FDA ApprovalFDA Decision
CE marking received for ACUVUE OASYS MAX 2-Week reusable contact lenses
▲EU ApprovalEx-US Regulatory
CE mark obtained for ACUVUE OASYS MAX 2-Week reusable contact lenses
●Poster PresentationAmivantamabApprovedPresentation
COPERNICUS prophylactic strategies data presented at WCLC 2026
EGFR-mutated advanced non-small cell lung cancersource ↗
●Oral PresentationAmivantamabApprovedPresentation
COPERNICUS data on prophylactic strategies presented at WCLC 2026
EGFR-mutated non-small cell lung cancersource ↗
●Additional DataAmivantamabApprovedClinical Data
COPERNICUS data on prophylactic strategies presented at WCLC 2026
EGFR-mutated non-small cell lung cancersource ↗
▲Long Term DataICOTYDEApprovedClinical Data
Two-year sustained skin clearance data through Week 112 in ICONIC-TOTAL
high-impact plaque psoriasissource ↗
▲Oral PresentationICOTYDEApprovedPresentation
Two-year ICONIC-TOTAL data presented at EADV Congress 2026
high-impact plaque psoriasissource ↗
▲FDA ApprovalIMAAVY™ApprovedFDA Decision
FDA approves IMAAVY for wAIHA
warm autoimmune hemolytic anemia (wAIHA)source ↗
▲EU ApprovalTECVAYLIApprovedEx-US Regulatory
European Commission approves TECVAYLI (teclistamab) plus daratumumab for RRMM
relapsed or refractory multiple myelomasource ↗
▲EU ApprovalTeclistamabApprovedEx-US Regulatory
EC genehmigt Typ-II-Änderung für teclistamab in Kombination mit daratumumab als Zweitlinientherapie bei RRMM
rezidiviertes oder refraktäres multiples Myelom (RRMM)source ↗
▲Priority ReviewRegulatory Filing
FDA grants Priority Review to sBLA for subcutaneous amivantamab in R/M HNSCC
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
●sBLA SubmissionRegulatory Filing
sBLA submitted for subcutaneous amivantamab in R/M HNSCC
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)source ↗
▲Partnership / LicenseCorporate
Johnson & Johnson announces collaboration with Sail Biomedicines to advance in vivo CAR-T programs
▼Equity OfferingCorporate
Johnson & Johnson makes $465 million equity investment in Sail Biomedicines
◆AcquisitionCorporate
Johnson & Johnson granted exclusive option to acquire Sail for $2.58 billion
▲AcquiredCorporate
Johnson & Johnson completes acquisition of Firefly Bio, Inc. for $1 billion in cash
●IP Litigation RulingIP / Competition
Proposed resolution of ovarian talc litigation with $5.5B commitment
ovarian cancersource ↗
◆License DisputeIP / Competition
Proposed comprehensive resolution of remaining talc litigation
ovarian talc litigationsource ↗
●Quarterly UpdateCorporate
Proposed resolution of ovarian talc litigation with $5.5B commitment, first payment up to $3B in 2027
▲Topline ReadoutTECVAYLIApprovedClinical Data
Positive topline results: Tec-Tal reduced risk of progression or death by 89% and risk of death by 62%
relapsed or refractory multiple myelomasource ↗
▲Topline ReadoutTALVEYApprovedClinical Data
Positive topline results: Tal-P reduced risk of progression or death by 73%
relapsed or refractory multiple myelomasource ↗
▲IP Litigation RulingIP / Competition
MDL court ordered plaintiffs to show cause why talc claims should not be dismissed
ovarian cancersource ↗
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP positive opinion for TECVAYLI in combination with daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
▲Full ResultsTECVAYLIApprovedClinical Data
Phase 3 MajesTEC-3 results: PFS and OS benefit with teclistamab + daratumumab vs standard of care
relapsed or refractory multiple myelomasource ↗
●Timing GuidancePresentation
In-process research and development charge of approximately $1 billion expected in Q3 2026
▲CHMP Positive OpinionTeclistamabApprovedEx-US Regulatory
CHMP recommends approval of teclistamab plus daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
▲Oral PresentationNipocalimabApprovedPresentation
New data from Vivacity-MG3 presented at EAN 2026 Congress
generalised myasthenia gravissource ↗
●Trial InitiationNipocalimabApprovedTrial
PETUNIA study design presented at EAN 2026
generalised myasthenia gravissource ↗
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP recommends approval of TECVAYLI plus daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
▲FDA ApprovalNipocalimabApprovedFDA Decision
EMA approval for gMG in adults and adolescents (12+) anti-AChR or anti-MuSK positive
generalised myasthenia gravissource ↗
▲Full ResultsTALVEYApprovedClinical Data
MonumenTAL-3 results presented at EHA 2026 and published in NEJM
relapsed/refractory multiple myelomasource ↗
▲Oral PresentationTALVEYApprovedPresentation
MonumenTAL-3 results presented at EHA 2026
relapsed/refractory multiple myelomasource ↗
▲PublicationTALVEYApprovedPresentation
MonumenTAL-3 results published in The New England Journal of Medicine
relapsed/refractory multiple myelomasource ↗
Past FDA Catalysts and PDUFA Decisions
How JNJ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-28 | Stelara (ustekinumab) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A87 / 100
Pipeline Score
$45.0B
Pipeline Value
$415.2B
Commercial Value
Overvalued
Valuation Signal
184
Drugs Scored
0.2x
rNPV / MCap
Top 1%
Large Pharma(rank 8 of 658)
Percentile Rank
Johnson & Johnson earns an A-grade pipeline score (87/100), with $45.0B risk-adjusted pipeline value, led by acetaminophen Caplet in Post Operative Dental Pain (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $97.9B x 4.2 = $415.2B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| DARZALEX | $15.7B | $12.9B | +22.3% |
| TREMFYA | $6.7B | $4.1B | +62.7% |
| STELARA | $4.2B | $8.3B | -49.5% |
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | $4.0B | $4.0B | -1% |
| ERLEADA | $3.8B | $3.3B | +18% |
| IMBRUVICA | $2.6B | $2.9B | -9.9% |
| Xarelto | $2.6B | $2.6B | +1.9% |
| Simponi/Simponi Aria | $2.6B | $2.4B | +5.6% |
| OPSUMIT/OPSYNVI | $2.4B | $2.3B | +7.6% |
| CARVYKTI | $2.3B | $1.4B | +63.4% |
| SPRAVATO | $2.0B | $1.3B | +53.2% |
| UPTRAVI | $2.0B | $1.9B | +5.5% |
Top 12 of 22 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| acetaminophen Caplet Small moleculeCompletedNCT02735122 | Post Operative Dental Pain | Phase 3 | COMPLETED | 420 | Oct 5, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every JNJ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IMAAVY Priority | generalized myasthenia gravis | Phase 2/3 | 2026-09-29 | mean change MG ADL: -2.88; mean change QMG: -8.25; corticosteroid reduction: initial patients 6, reduced dose 3, discontinued 1Read More | Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schmid TimothyOfficer (EVP, WW Chair, MedTech) | Option | 11,070 36,517 held | $131.94 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JNJ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 13.3 % (-6.3 %) | 107.92 M | 424.94 K | 2.52% ( 10.44 K) |
JNJ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JNJ ranks across every disease it competes in
Competitive Position is a premium feature
See how JNJ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJNJ News
JNJJohnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson has released new two-year data from the Phase 3 ICONIC-TOTAL study, demonstrating the effectiveness of ICOTYDE (icotrokinra) in treating high-impact plaque psoriasis. This targeted oral peptide shows sustained skin clearance and a favorable safety profile, making it a significant advancement in psoriasis treatment. The data were presented at the EADV Congress 2026, emphasizing its potential as a first-line systemic therapy.
Read more →JNJNew Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Johnson & Johnson's new survey reveals that while most women understand menopause affects mood and sleep, only 40% associate it with changes in eye health. The survey highlights a significant gap in awareness, with many women not seeking necessary eye care. The company, alongside Naomi Watts and the American Optometric Association, aims to encourage women to prioritize eye health during midlife.
Read more →JNJJohnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Johnson & Johnson has announced new data on IMAAVY (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG), highlighting sustained disease control and improved patient outcomes over a two-year period. The findings indicate significant improvements in daily functioning and muscle strength, along with a reduction in corticosteroid use. Additionally, a survey revealed that many patients previously dissatisfied with their treatment experienced positive results after switching to IMAAVY.
Read more →JNJJohnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Johnson & Johnson announced that TREMFYA (guselkumab) is the first IL-23 inhibitor to demonstrate significant improvements in spinal pain and stiffness in the Phase 4 STAR study for patients with axial psoriatic arthritis. The study met primary and major secondary endpoints, showing both improvement in axial symptoms and reduction in inflammation. The findings support TREMFYA as a first-line treatment option for this patient population.
Read more →JNJSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Johnson & Johnson announced that 50% of patients with early line relapsed/refractory multiple myeloma achieved five-year treatment-free remission after a single infusion of CARVYKTI (ciltacabtagene autoleucel) in the Phase 2 CARTITUDE-2 study. These results suggest that earlier treatment may enhance long-term remission rates. The safety profile remains consistent, with no new CAR T-cell-related neurotoxicity reported, although some patients experienced serious adverse events.
Read more →JNJNew model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Johnson & Johnson announced promising data from the Phase 3 MajesTEC-3 study, demonstrating that TECVAYLI (teclistamab-cqyv) combined with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) significantly improves overall survival in patients with relapsed or refractory multiple myeloma. The study indicates that approximately 87% of patients may have a mortality risk comparable to that of the general population. The findings suggest a potential shift in long-term survival expectations for this patient group.
Read more →JNJDer CHMP empfiehlt die Zulassung von TECVAYLI®▼ (teclistamab) von Johnson & Johnson zur Behandlung des rezidivierten bzw. refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie
The CHMP has recommended the approval of TECVAYLI (teclistamab) by Johnson & Johnson for treating relapsed or refractory multiple myeloma (RRMM) after at least one prior therapy. This recommendation is based on positive results from a Phase III study demonstrating significant improvements in progression-free and overall survival compared to standard therapies. Teclistamab's potential to enhance treatment options for RRMM patients is emphasized, despite some concerns regarding infection rates and adverse events.
Read more →JNJCAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Johnson & Johnson announced positive topline results from a pivotal Phase 3 study of CAPLYTA (lumateperone) for treating manic episodes in bipolar I disorder. The study demonstrated a significant reduction in symptoms as early as Day 3, with sustained improvements through Week 3. These findings support CAPLYTA's potential to effectively manage acute mania, although it is not yet approved for this indication.
Read more →JNJCHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy
The CHMP has recommended the approval of Johnson & Johnson's TECVAYLI® (teclistamab) for adult patients with relapsed/refractory multiple myeloma who have received at least one prior therapy. This recommendation follows positive results from the Phase 3 MajesTEC-9 study, which demonstrated significant improvements in both progression-free and overall survival compared to standard treatments. The approval reflects a commitment to providing innovative therapies that address evolving patient needs in multiple myeloma.
Read more →JNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Johnson & Johnson reported positive results from the Phase 2b COPERNICUS study, showing that RYBREVANT FASPRO combined with LAZCLUZE results in low rates of treatment-related events for patients with advanced non-small cell lung cancer. The study emphasizes a patient-centric approach with less frequent dosing and effective prophylactic strategies. The findings were presented at the IASLC 2026 World Conference on Lung Cancer.
Read more →JNJJohnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
Johnson & Johnson announced that amivantamab combined with chemotherapy resulted in a median overall survival of 34.3 months for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer. This marks a significant improvement over the 27.9 months median survival with chemotherapy alone. The results, presented at the IASLC 2026 World Conference, emphasize the treatment's potential to reset survival expectations for this challenging patient population.
Read more →JNJJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy has shown promising results in the Phase 3 PAPILLON study for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The treatment achieved a median overall survival of 34.3 months, significantly extending survival compared to chemotherapy alone, which had a median of 27.9 months. This represents a notable advancement for a patient population with historically low survival rates.
Read more →JNJJohnson & Johnson reçoit le marquage CE pour les lentilles de contact réutilisables ACUVUE OASYS MAX
Johnson & Johnson has announced that it received CE marking for its new reusable contact lens, ACUVUE OASYS MAX 2-Week. This lens features exclusive MAX technologies aimed at providing enhanced comfort and visual clarity, even on day 14 of use. The product is set to launch in select European countries later this year, with a broader rollout planned for 2027.
Read more →JNJJohnson & Johnson erhält CE-Kennzeichnung für wiederverwendbare Kontaktlinsen der Marke ACUVUE OASYS MAX
Johnson & Johnson has announced that it has received CE marking for its new ACUVUE OASYS MAX 2-Week reusable contact lenses. These lenses incorporate proprietary MAX technologies designed to provide exceptional comfort and clear vision even on the 14th day of use. The product is set to launch in select European countries later this year, with a broader rollout planned for 2027.
Read more →JNJResumen: Johnson & Johnson obtiene el marcado CE para las lentillas reutilizables ACUVUE OASYS MAX
Johnson & Johnson has announced the receipt of CE marking for its new ACUVUE OASYS MAX 2-Week reusable contact lenses. These lenses incorporate patented MAX technologies aimed at providing enhanced comfort and visual clarity for users, even on the 14th day of wear. This approval marks a significant advancement in their product line.
Read more →JNJRiassunto: Johnson & Johnson riceve il marchio CE per le lenti a contatto riutilizzabili ACUVUE OASYS MAX
Johnson & Johnson has announced the receipt of the CE mark for its new ACUVUE OASYS MAX 2-Week reusable contact lenses. These lenses utilize proprietary MAX technologies to provide superior comfort and maintain clear vision even after 14 days of use. This approval marks a significant advancement in their product offerings.
Read more →JNJSamenvatting: Johnson & Johnson ontvangt CE-markering voor herbruikbare ACUVUE OASYS MAX-contactlenzen
Johnson & Johnson has announced the receipt of CE marking for its new ACUVUE OASYS MAX 2-Week contact lenses. These reusable lenses incorporate MAX technologies aimed at providing enhanced comfort and visual clarity throughout their 14-day usage period. This approval marks a significant advancement in their product offerings.
Read more →JNJJohnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
Johnson & Johnson has received CE Marking for its new ACUVUE OASYS MAX 2-Week reusable contact lenses, designed to enhance comfort and visual clarity. The lenses incorporate advanced MAX technologies and will be launched in select European markets starting late 2026, with broader availability planned for 2027. This product aims to meet the increasing demand for comfortable vision solutions in a digital world.
Read more →JNJJohnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
Johnson & Johnson presented 24 abstracts at the 2026 Psych Congress, highlighting new clinical data on neuropsychiatry treatments. Key presentations included pivotal Phase 3 data for CAPLYTA in bipolar mania and analyses of SPRAVATO's effects on depressive symptoms. The company aims to enhance treatment options for patients facing significant challenges in managing mood disorders.
Read more →JNJJohnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
Johnson & Johnson will present at the Deutsche Bank 2026 Healthcare Summit on September 17, 2026. The management team will engage in a Fireside Chat at 12:00 p.m. Eastern Time. Investors can access a live audio webcast through the company's Investor Relations website, with an archived version available later.
Read more →About Johnson & Johnson
HeadquartersONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
BIOPHARMAWATCH ELITE PLUS
Trade the next JNJ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime